Grimes & Company’s Idexx Laboratories IDXX Stock Holding History

Grimes & Company’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Sell	4,274 -9	-0.2%	-$5.05K	0.05%	186
2026 Q1	$2.41M	Sell	4,283 -34	-0.8%	-$21.8K	0.07%	171
2025 Q4	$2.92M	Sell	4,317 -84	-2%	-$57.2K	0.07%	162
2025 Q3	$2.81M	Sell	4,401 -67	-1%	-$40.7K	0.07%	156
2025 Q2	$2.4M	Sell	4,468 -34	-0.8%	-$16.3K	0.07%	153
2025 Q1	$1.89M	Buy	4,502 +29	+0.6%	+$12.6K	0.06%	145
2024 Q4	$1.85M	Sell	4,473 -229	-5%	-$100K	0.05%	156
2024 Q3	$2.38M	Buy	4,702 +1	+0%	+$486	0.06%	135
2024 Q2	$2.29M	Buy	4,701 +60	+1%	+$30.1K	0.07%	127
2024 Q1	$2.51M	Sell	4,641 -58	-1%	-$31.7K	0.08%	124
2023 Q4	$2.61M	Buy	4,699 +273	+6%	+$128K	0.09%	117
2023 Q3	$1.94M	Buy	4,426 +1	+0%	+$499	0.07%	126
2023 Q2	$2.22M	Buy	4,425 +8	+0.2%	+$3.83K	0.08%	115
2023 Q1	$2.21M	Sell	4,417 -3	-0.1%	-$1.44K	0.09%	111
2022 Q4	$1.8M	Buy	4,420 +114	+3%	+$44.3K	0.08%	130
2022 Q3	$1.4M	Hold	4,306	–	–	0.07%	122
2022 Q2	$1.51M	Hold	4,306	–	–	0.08%	122
2022 Q1	$2.36M	Sell	4,306 -15	-0.3%	-$7.89K	0.12%	113
2021 Q4	$2.85M	Hold	4,321	–	–	0.13%	102
2021 Q3	$2.69M	Hold	4,321	–	–	0.12%	105
2021 Q2	$2.73M	Hold	4,321	–	–	0.12%	104
2021 Q1	$2.11M	Hold	4,321	–	–	0.1%	110
2020 Q4	$2.16M	Hold	4,321	–	–	0.11%	108
2020 Q3	$1.7M	Hold	4,321	–	–	0.11%	106
2020 Q2	$1.43M	Hold	4,321	–	–	0.1%	108
2020 Q1	$1.05M	Hold	4,321	–	–	0.1%	115
2019 Q4	$1.13M	Hold	4,321	–	–	0.07%	129
2019 Q3	$1.18M	Hold	4,321	–	–	0.08%	125
2019 Q2	$1.19M	Sell	4,321 -750	-15%	-$185K	0.09%	117
2019 Q1	$1.13M	Buy	5,071 +221	+5%	+$45.6K	0.09%	113
2018 Q4	$902K	Hold	4,850	–	–	0.09%	111
2018 Q3	$1.21M	Hold	4,850	–	–	0.1%	108
2018 Q2	$1.06M	Sell	4,850 -2,950	-38%	-$608K	0.09%	117
2018 Q1	$1.49M	Buy	7,800 +100	+1%	+$18.5K	0.14%	103
2017 Q4	$1.2M	Hold	7,700	–	–	0.12%	105
2017 Q3	$1.2M	Hold	7,700	–	–	0.13%	99
2017 Q2	$1.24M	Hold	7,700	–	–	0.14%	102
2017 Q1	$1.19M	Hold	7,700	–	–	0.13%	101
2016 Q4	$903K	Hold	7,700	–	–	0.1%	109
2016 Q3	$868K	Buy	7,700 +100	+1%	+$10.5K	0.12%	109
2016 Q2	$706K	Hold	7,600	–	–	0.09%	113
2016 Q1	$595K	Hold	7,600	–	–	0.08%	113
2015 Q4	$554K	Hold	7,600	–	–	0.07%	115
2015 Q3	$564K	Hold	7,600	–	–	0.07%	111
2015 Q2	$487K	Hold	7,600	–	–	0.07%	112
2015 Q1	$587K	Hold	7,600	–	–	0.14%	89
2014 Q4	$563K	Hold	7,600	–	–	0.15%	97
2014 Q3	$448K	Hold	7,600	–	–	0.12%	99
2014 Q2	$508K	Hold	7,600	–	–	0.13%	96
2014 Q1	$461K	Hold	7,600	–	–	0.13%	95
2013 Q4	$404K	Hold	7,600	–	–	0.12%	96
2013 Q3	$379K	Hold	7,600	–	–	0.13%	93
2013 Q2	$341K	Buy	+7,600	New	+$332K	0.12%	92

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Grimes & Company's IDXX Position: Q2 2026 in Review

Grimes & Company reduced its Idexx Laboratories (IDXX) stake by 0.21% in Q2 2026, selling an estimated $5.05K and leaving 4,274 shares worth $2.25M. The position accounts for 0.05% of the portfolio, ranked #186.

Grimes & Company first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.92M in Q4 2025. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Grimes & Company held 4,274 shares of Idexx Laboratories worth $2.25M as of Q2 2026.
Grimes & Company sold 9 Idexx Laboratories shares in Q2 2026, an estimated $5.05K.
Idexx Laboratories made up 0.05% of Grimes & Company's portfolio in Q2 2026, its #186 holding.
Grimes & Company first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
Grimes & Company's Idexx Laboratories position peaked at $2.92M in Q4 2025.
1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.